GlassScriptPhysician profile
Joy K Schindler
NPI 1356976997
$1,684.34
in general payments reported to CMS, 2019-2025
15 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $26.09 · 2023: $275 · 2024: $564 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.43 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $291.41 | 2024-2025 | Jakafi, Jakafi, Niktimvo |
| Abbvie INC. | $281.54 | 2023-2024 | |
| Glaxosmithkline, LLC. | $203.83 | 2021 | |
| Astellas Pharma US INC | $196.06 | 2024-2025 | Cresemba, Xospata |
| Sanofi-Aventis U.S. LLC | $150.93 | 2023-2025 | |
| Sobi, INC | $140.46 | 2024-2025 | |
| Janssen Biotech, INC. | $125.54 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Jazz Pharmaceuticals INC. | $59.69 | 2025 | |
| Celgene Corporation | $52.74 | 2022-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $34.73 | 2025 | Prevymis, Zerbaxa |
| Genzyme Corporation | $32.99 | 2024 | |
| Syndax Pharmaceuticals, INC. | $30.63 | 2025 | |
| Janssen Scientific Affairs, LLC | $29.81 | 2023 | Tecvayli |
| Seagen INC. | $27.95 | 2023 | Adcetris |
| Legend Biotech USA INC. | $26.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Schindler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.